STOCK TITAN

Guardant Health Inc - GH STOCK NEWS

Welcome to our dedicated news page for Guardant Health (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Guardant Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Guardant Health's position in the market.

Rhea-AI Summary
Guardant Health, Inc. will be hosting an Investor Day on September 7, 2023, in New York City. The event will feature presentations by several members of the company's leadership team. Interested parties can access a live and archived webcast of the presentation on the company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
conferences
-
Rhea-AI Summary
Guardant Health reports Q2 2023 financial results with a 26% increase in revenue year over year. Raises 2023 revenue guidance to $545-550 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.42%
Tags
earnings
-
Rhea-AI Summary
Guardant Health, Inc. (GH) announces resolution of pending litigation and extension of commercial partnership with Illumina Inc. (ILMN). The three-year agreement includes dismissal of pending litigation, collaboration on cancer research, and a new long-term purchase and supply commitment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
partnership
Rhea-AI Summary
Guardant Health, Inc. (GH) announces resolution of pending litigation and extension of commercial partnership with Illumina Inc. (ILMN). The three-year agreement includes dismissal of pending litigation, collaboration on cancer research, and a new long-term purchase and supply commitment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
partnership
-
Rhea-AI Summary
Blue Cross and Blue Shield of Louisiana now offers coverage for the Guardant Reveal™ molecular residual disease (MRD) test. The test detects circulating tumor DNA in blood after treatment to help identify cancer patients with residual or recurring disease. It is the first blood-only liquid biopsy test available for MRD testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences earnings
Rhea-AI Summary
Guardant Health has received national reimbursement approval from the Japanese Ministry of Health, Labor and Welfare for its Guardant360 CDx liquid biopsy test for comprehensive genomic profiling. The test analyzes circulating tumor DNA to provide genomic profiling for all solid tumor cancers. This approval represents a significant milestone for the company as Japan is the first country in the Asia-Pacific region to reimburse the use of the test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
-
Rhea-AI Summary
Guardant Health will present data from 17 studies at the 2023 ASCO Annual Meeting, showcasing the value of their Guardant blood tests and real-world data in precision oncology and cancer screening. The research highlights the potential of epigenomic analysis through the Guardant Infinity platform to identify new biomarker targets and predict treatment resistance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
conferences
-
Rhea-AI Summary
Singapore's Health Sciences Authority approves Guardant360 CDx, a comprehensive genomic profiling blood test for advanced solid cancers. The test is also approved as a companion diagnostic for TAGRISSO in non-small cell lung cancer. This is the first blood test approved for comprehensive genomic profiling for all solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
conferences
Guardant Health Inc

Nasdaq:GH

GH Rankings

GH Stock Data

2.51B
116.66M
4.15%
92.19%
6.37%
Dental Laboratories
Manufacturing
Link
United States
Palo Alto

About GH

we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.